medigraphic.com
ISSN 1561-3046 (Electronic)

2022, Number 3

<< Back Next >>

Rev Cub Med Mil 2022; 51 (3)

Clinical evolution of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a

Vázquez-Gómez LA, Hidalgo MC, Broche-Pérez Y

Language: Spanish
References: 15
Page:
PDF size: 267.18 Kb.


ABSTRACT

Introduction: The initiation of interferon therapy has been and is the first step in the treatment of many patients with multiple sclerosis, with the aim of delaying the progression of the disease.
Objective: To identify the clinical markers of response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Methods: An observational, descriptive, longitudinal, prospective study was carried out of a series of cases of patients diagnosed with relapsing-remitting multiple sclerosis, who received treatment with interferon beta-1a, in the period between January 2014 and December 2020. All 39 patients were included.
Results: The mean age was 34.54 years. The mean disability level at baseline, 12, 24, and 36 months was 1.76; 1.91; 2.1 and 2.37 respectively. The mean number of flares at baseline, 12, 24, and 36 months was 1.13; 0.26; 0.38 and 0.13 respectively. The number of progressions lower by 51% at 36 months is shown. The odds ratio for the absence of relapses is between 2 and 4 times in these patients.
Conclusions: Clinical markers of response to treatment with Interferon beta-1a are identified that help assess the response to treatment, which has a positive impact on the evolution of the disease.


REFERENCES

  1. Lucchetta RC, Tonin FS, Borba HHL, Leonart LP, Ferreira VL, Bonetti AF, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs. 2018 [acceso: 15/05/2021]; 32(9):[aprox. 13 p.]. Disponible en: http://link.springer.com/article/10.1007/s40263-018-0541-51.

  2. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018 [acceso: 15/05/2021]; 24(2): [aprox. 25 p.]. Disponible en: http://journals.sagepub.com/doi/abs/10.1177/13524585177510492.

  3. Fernández O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, et al. Revision de las novedades del Congreso ECTRIMS 2017, presentadas en la X Reunion Post-ECTRIMS (II). Rev Neurol. 2018 [acceso: 15/05/2021]; 67(2):[aprox. 12 p.]. Disponible en: http://pesquisa.bvsalud.org/portal/resource/pt/ibc-174870?lang=es3.

  4. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 [acceso: 15/05/2021]; 391(10130):[aprox. 14 p.]. Disponible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30481-1/fulltext4.

  5. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 [acceso:15/05/2021]; 17(2):[aprox. 50 p.]. Disponible en: http://discovery.ucl.ac.uk/id/eprint/10041020/1/Barkhof_Diagnostic%20criteria_revision%201_final_10OCT2017.pdf5.

  6. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. WMA; 2018. [acceso: 01/04/2021]. Disponible en: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/6.

  7. Alenda Asensi R. Biomarcadores de respuesta al interferón beta en la esclerosis múltiple [Tesis doctoral]. España: Universidad Complutense de Madrid; 2016. [acceso:15/05/2021]. Disponible en: Disponible en: http://eprints.ucm.es/id/eprint/44444 7.

  8. Traboulsee A, Li DK, Cascione M, Fang J, Dangond F, Miller A. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. BMC Neurol. 2018 [acceso: 15/05/2021]; 18(1):[aprox. 9 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC61378878.

  9. Drulovic J, Ivanovic J, Mesaros S, Martinovic V, Kisic-Tepavcevic D, Dujmovic I, et al. Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study. Neurol Sci . 2019 [acceso: 15/05/2021]; 40(8):[aprox. 20 p.]. Disponible en: http://link.springer.com/article/10.1007/s10072-019-03878-49.

  10. Alcoriza Rodríguez S, Morais Vargas C. Esclerosis múltiple [Trabajo de fin de grado]. España, Madrid: Universidad Complutense; 2015. [acceso: 15/05/2021]. Disponible en: Disponible en: http://eprints.ucm.es/id/eprint/48467 10.

  11. Castilló Justribó J. Indicadores precoces de respuesta al tratamiento con interferón en pacientes con esclerosis múltiple [Tesis doctoral]. España, Barcelona: Universitat Autònoma de Barcelona; 2016. [acceso: 15/05/2021]. Disponible en: Disponible en: http://www.tdx.cat/handle/10803/400286 11.

  12. Newsome SD, Scott TF, Arnold DL, Altincatal A, Naylor ML. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. Mult Scler Relat Disord. 2022 [acceso: 05/04/2022]; 57: [aprox. 7 p.]. Disponible en: http://www.sciencedirect.com/science/article/pii/S221103482100634912.

  13. Cardentey Sánchez R, Díaz de la Fe A, Peláez Suarez A, Grass D, Morgado Vega T, Sánchez Canal A, et al. Interferon beta 1a (Rebif(r)) in relapsing remitting multiple sclerosis. Drug Dev Res. 2021 [acceso: 10/08/2021]; 82(5):[aprox. 8 p.]. Disponible en: http://onlinelibrary.wiley.com/doi/abs/10.1002/ddr.2179813.

  14. Gençer G, Demirkaya S, Semai B, Odabasi Z. Clinical, radiological and electrophysiological comparison of immunomodulatory therapies in multiple sclerosis. Arch Neuropsychiatry. 2017 [acceso: 15/05/2021]; 54(2): [aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491660/14.

  15. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, et al. Defining the response to interferon-ß in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006 [acceso: 15/05/2021]; 59(2): [aprox. 8 p.]. Disponible en: http://onlinelibrary.wiley.com/doi/abs/10.1002/ana.2074015.




2020     |     www.medigraphic.com